First Header Logo Second Header Logo

Connection

Anthony Atala to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Anthony Atala has written about Prostatic Neoplasms.
Anthony Atala
Connection Strength
30.171
Prostatic Neoplasms
  1. Atala A. Uro-Science. J Urol. 2021 02; 205(2):632-633.
    View in: PubMed
    Score: 0.513
  2. Atala A. Re: Regenerative Potential of Prostate Luminal Cells Revealed by Single-Cell Analysis. J Urol. 2020 12; 204(6):1384.
    View in: PubMed
    Score: 0.507
  3. Atala A. Re: Genome-Wide Plasma DNA Methylation Features of Metastatic Prostate Cancer. J Urol. 2020 11; 204(5):1100-1101.
    View in: PubMed
    Score: 0.504
  4. Atala A. Re: Noncoding Mutations Target Cis-Regulatory Elements of the FOXA1 Plexus in Prostate Cancer. J Urol. 2020 11; 204(5):1100.
    View in: PubMed
    Score: 0.504
  5. Atala A. Re: OXPHOS Remodeling in High-Grade Prostate Cancer Involves mtDNA Mutations and Increased Succinate Oxidation. J Urol. 2020 10; 204(4):881-882.
    View in: PubMed
    Score: 0.502
  6. Atala A. Re: Long Noncoding RNA DRAIC Inhibits Prostate Cancer Progression by Interacting with IKK to Inhibit NF-?B Activation. J Urol. 2020 09; 204(3):622.
    View in: PubMed
    Score: 0.498
  7. Atala A. Re: Ga-13 Induces C X C Motif Chemokine Ligand 5 Expression in Prostate Cancer Cells by Transactivating NF-?B. J Urol. 2020 08; 204(2):390.
    View in: PubMed
    Score: 0.495
  8. Atala A. Re: miR-191 Promotes Radiation Resistance of Prostate Cancer through Interaction with RXRA. J Urol. 2020 07; 204(1):188.
    View in: PubMed
    Score: 0.492
  9. Atala A. Re: High-Fat Diet Fuels Prostate Cancer Progression by Rewiring the Metabolome and Amplifying the MYC Program. J Urol. 2020 05; 203(5):886.
    View in: PubMed
    Score: 0.486
  10. Atala A. Re: The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. J Urol. 2020 04; 203(4):665-666.
    View in: PubMed
    Score: 0.484
  11. Atala A. Re: Selective Targeting of PARP-2 Inhibits Androgen Receptor Signaling and Prostate Cancer Growth through Disruption of FOXA1 Function. J Urol. 2020 04; 203(4):665.
    View in: PubMed
    Score: 0.484
  12. Atala A. Re: The Androgen Receptor Regulates a Druggable Translational Regulon in Advanced Prostate Cancer. J Urol. 2020 03; 203(3):466.
    View in: PubMed
    Score: 0.480
  13. Atala A. Re: Betaglycan Drives the Mesenchymal Stromal Cell Osteogenic Program and Prostate Cancer-Induced Osteogenesis. J Urol. 2020 03; 203(3):465-466.
    View in: PubMed
    Score: 0.480
  14. Atala A. Re: Dysregulation of p53-RBM25-Mediated circAMOTL1L Biogenesis Contributes to Prostate Cancer Progression through the circAMOTL1L-miR-193a-5p-Pcdha Pathway. J Urol. 2020 02; 203(2):256-257.
    View in: PubMed
    Score: 0.477
  15. Atala A. Re: Distinct Structural Classes of Activating FOXA1 Alterations in Advanced Prostate Cancer. J Urol. 2020 01; 203(1):35-36.
    View in: PubMed
    Score: 0.475
  16. Atala A. Re: Communication of Prostate Cancer Cells with Bone Cells via Extracellular Vesicle RNA; a Potential Mechanism of Metastasis. J Urol. 2019 12; 202(6):1101.
    View in: PubMed
    Score: 0.472
  17. Atala A. Re: The Proteogenomic Landscape of Curable Prostate Cancer. J Urol. 2019 10; 202(4):664.
    View in: PubMed
    Score: 0.472
  18. Atala A. Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. J Urol. 2019 09; 202(3):460-461.
    View in: PubMed
    Score: 0.469
  19. Atala A. Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. J Urol. 2019 08; 202(2):214.
    View in: PubMed
    Score: 0.466
  20. Atala A. Re: Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. J Urol. 2019 08; 202(2):213-214.
    View in: PubMed
    Score: 0.466
  21. Atala A. Re: Targeting FOXA1-Mediated Repression of TGF-ß Signaling Suppresses Castration-Resistant Prostate Cancer Progression. J Urol. 2019 07; 202(1):36.
    View in: PubMed
    Score: 0.464
  22. Atala A. Re: Alterations of Tumor Microenvironment by Nitric Oxide Impedes Castration-Resistant Prostate Cancer Growth. J Urol. 2019 07; 202(1):35-36.
    View in: PubMed
    Score: 0.464
  23. Atala A. Re: Immunogenomic Analyses Associate Immunological Alterations with Mismatch Repair Defects in Prostate Cancer. J Urol. 2019 05; 201(5):861-862.
    View in: PubMed
    Score: 0.460
  24. Atala A. Re: Classification of Prostate Cancer Using a Protease Activity Nanosensor Library. J Urol. 2019 05; 201(5):862-863.
    View in: PubMed
    Score: 0.460
  25. Atala A. Re: Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. J Urol. 2019 04; 201(4):668.
    View in: PubMed
    Score: 0.458
  26. Atala A. Re: Large-Scale Transcriptome-Wide Association Study Identifies New Prostate Cancer Risk Regions. J Urol. 2019 03; 201(3):447.
    View in: PubMed
    Score: 0.455
  27. Atala A. Re: A Somatically Acquired Enhancer of the Androgen Receptor is a Noncoding Driver in Advanced Prostate Cancer. J Urol. 2019 02; 201(2):230.
    View in: PubMed
    Score: 0.453
  28. Atala A. Re: Acquisition of Tumorigenic Potential and Therapeutic Resistance in CD133+ Subpopulation of Prostate Cancer Cells Exhibiting Stem-Cell Like Characteristics. J Urol. 2019 01; 201(1):33.
    View in: PubMed
    Score: 0.450
  29. Atala A. Re: Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer. J Urol. 2018 10; 200(4):701-702.
    View in: PubMed
    Score: 0.436
  30. Atala A. Re: An Aberrant SREBP-Dependent Lipogenic Program Promotes Metastatic Prostate Cancer. J Urol. 2018 09; 200(3):501-502.
    View in: PubMed
    Score: 0.432
  31. Atala A. Re: Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation. J Urol. 2018 05; 199(5):1115-1116.
    View in: PubMed
    Score: 0.424
  32. Atala A. Re: Prostate Cancer-Associated SPOP Mutations Confer Resistance to BET Inhibitors through Stabilization of BRD4. J Urol. 2018 04; 199(4):895-896.
    View in: PubMed
    Score: 0.421
  33. Atala A. Re: The Metabolic Co-Regulator PGC1a Suppresses Prostate Cancer Metastasis. J Urol. 2017 12; 198(6):1212-1214.
    View in: PubMed
    Score: 0.412
  34. Atala A. Re: Genomic Hallmarks of Localized, Non-Indolent Prostate Cancer. J Urol. 2017 12; 198(6):1213.
    View in: PubMed
    Score: 0.412
  35. Atala A. Re: Genome-Wide Association Study of Prostate-Specific Antigen Levels Identifies Novel Loci Independent of Prostate Cancer. J Urol. 2017 10; 198(4):747.
    View in: PubMed
    Score: 0.407
  36. Atala A. Re: AKT-Mediated Stabilization of Histone Methyltransferase WHSC1 Promotes Prostate Cancer Metastasis. J Urol. 2017 09; 198(3):485-487.
    View in: PubMed
    Score: 0.404
  37. Atala A. Re: SOX2 Promotes Lineage Plasticity and Antiandrogen Resistance in TP53- and RB1-Deficient Prostate Cancer. J Urol. 2017 08; 198(2):259.
    View in: PubMed
    Score: 0.402
  38. Atala A. Re: Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance. J Urol. 2017 07; 198(1):102-104.
    View in: PubMed
    Score: 0.399
  39. Atala A. Urological Tissue Cultures. J Urol. 2017 02; 197(2S):S15-S16.
    View in: PubMed
    Score: 0.391
  40. Atala A. Re: Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. J Urol. 2017 03; 197(3 Pt 1):701-702.
    View in: PubMed
    Score: 0.391
  41. Atala A. Re: Integrative Analyses Reveal a Long Noncoding RNA-Mediated Sponge Regulatory Network in Prostate Cancer. J Urol. 2017 03; 197(3 Pt 1):701.
    View in: PubMed
    Score: 0.391
  42. Atala A. Re: The Metabolic Co-Regulator PGC1a Suppresses Prostate Cancer Metastasis. J Urol. 2017 02; 197(2):402-403.
    View in: PubMed
    Score: 0.388
  43. Atala A. Re: N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. J Urol. 2016 11; 196(5):1584-1585.
    View in: PubMed
    Score: 0.382
  44. Atala A. Re: Autophagy Defects Suggested by Low Levels of Autophagy Activator MAP1S and High Levels of Autophagy Inhibitor LRPPRC Predict Poor Prognosis of Prostate Cancer Patients. J Urol. 2016 06; 195(6):1948-9.
    View in: PubMed
    Score: 0.371
  45. Atala A. Re: Sex Hormone-Dependent tRNA Halves Enhance Cell Proliferation in Breast and Prostate Cancers. J Urol. 2016 04; 195(4 Pt 1):1168-9.
    View in: PubMed
    Score: 0.367
  46. Atala A. Re: Expression of Nuclear Matrix Proteins Binding Matrix Attachment Regions in Prostate Cancer. PARP-1: New Player in Tumor Progression. J Urol. 2016 Mar; 195(3):801.
    View in: PubMed
    Score: 0.364
  47. Atala A. Re: Elf5 Inhibits TGF-ß-Driven Epithelial-Mesenchymal Transition in Prostate Cancer by Repressing SMAD3 Activation. J Urol. 2016 Jan; 195(1):221.
    View in: PubMed
    Score: 0.363
  48. Atala A. Re: PLCe Knockdown Inhibits Prostate Cancer Cell Proliferation via Suppression of Notch Signalling and Nuclear Translocation of the Androgen Receptor. J Urol. 2016 Feb; 195(2):524-5.
    View in: PubMed
    Score: 0.361
  49. Atala A. Re: Regulation of the ITGA2 Gene by Epigenetic Mechanisms in Prostate Cancer. J Urol. 2016 Feb; 195(2):525.
    View in: PubMed
    Score: 0.361
  50. Atala A. Re: A Feedback Regulation between miR-145 and DNA Methyltransferase 3b in Prostate Cancer Cell and Their Responses to Irradiation. J Urol. 2015 Dec; 194(6):1823-4.
    View in: PubMed
    Score: 0.358
  51. Atala A. Re: The Inhibitor of Differentiation Isoform Id1b, Generated by Alternative Splicing, Maintains Cell Quiescence and Confers Self-Renewal and Cancer Stem Cell-Like Properties. J Urol. 2015 Oct; 194(4):1163.
    View in: PubMed
    Score: 0.354
  52. Atala A. Re: SAHA Triggered MET Activation Contributes to SAHA Tolerance in Solid Cancer Cells. J Urol. 2015 Sep; 194(3):848-9.
    View in: PubMed
    Score: 0.352
  53. Atala A. Re: A Human Prostatic Bacterial Isolate Alters the Prostatic Microenvironment and Accelerates Prostate Cancer Progression. J Urol. 2015 Sep; 194(3):849.
    View in: PubMed
    Score: 0.352
  54. Atala A. Re: Ion Channel TRPM8 Promotes Hypoxic Growth of Prostate Cancer Cells via an O2-Independent and RACK1-Mediated Mechanism of HIF-1a Stabilization. J Urol. 2015 Jul; 194(1):260.
    View in: PubMed
    Score: 0.348
  55. Atala A. Re: Bone-Induced c-Kit Expression in Prostate Cancer: A Driver of Intraosseous Tumor Growth. J Urol. 2015 Jul; 194(1):260.
    View in: PubMed
    Score: 0.348
  56. Atala A. Re: Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer. J Urol. 2015 Jun; 193(6):2146-7.
    View in: PubMed
    Score: 0.346
  57. Atala A. Re: Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. J Urol. 2015 Jun; 193(6):2146.
    View in: PubMed
    Score: 0.346
  58. Atala A. Re: Identification and characterization of membrane androgen receptors in the ZIP9 zinc transporter subfamily: II. Role of human ZIP9 in testosterone-induced prostate and breast cancer cell apoptosis. J Urol. 2015 Jun; 193(6):2147.
    View in: PubMed
    Score: 0.346
  59. Atala A. Re: Estrogen receptor ß upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. J Urol. 2015 May; 193(5):1725.
    View in: PubMed
    Score: 0.344
  60. Atala A. Re: Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy. J Urol. 2015 Apr; 193(4):1441-2.
    View in: PubMed
    Score: 0.342
  61. Atala A. Re: Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. J Urol. 2015 Apr; 193(4):1442.
    View in: PubMed
    Score: 0.342
  62. Atala A. Re: Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer. J Urol. 2015 Jan; 193(1):368.
    View in: PubMed
    Score: 0.336
  63. Atala A. Re: The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. J Urol. 2014 Aug; 192(2):613.
    View in: PubMed
    Score: 0.326
  64. Atala A. Re: TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. J Urol. 2014 Jun; 191(6):1927.
    View in: PubMed
    Score: 0.323
  65. Atala A. Re: bispecific small molecule-antibody conjugate targeting prostate cancer. J Urol. 2014 Jun; 191(6):1927-8.
    View in: PubMed
    Score: 0.323
  66. Atala A. Re: Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors. J Urol. 2014 Apr; 191(4):1181.
    View in: PubMed
    Score: 0.319
  67. Atala A. Re: enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated salmonella carrying a plasmid co-expressing p53 gene and MDM2 siRNA. J Urol. 2014 Mar; 191(3):866-7.
    View in: PubMed
    Score: 0.316
  68. Atala A. Re: telomere length influences cancer cell differentiation in vivo. J Urol. 2014 Mar; 191(3):867-8.
    View in: PubMed
    Score: 0.316
  69. Atala A. Re: CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. J Urol. 2014 Jan; 191(1):270-1.
    View in: PubMed
    Score: 0.313
  70. Atala A. Re: Aire-dependent thymic development of tumor-associated regulatory T cells. J Urol. 2013 Nov; 190(5):1954.
    View in: PubMed
    Score: 0.309
  71. Atala A. Re: p21-activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2). J Urol. 2013 Sep; 190(3):1131.
    View in: PubMed
    Score: 0.306
  72. Atala A. Re.: A novel imaging approach for early detection of prostate cancer based on endogenous zinc sensing. J Urol. 2011 May; 185(5):1976.
    View in: PubMed
    Score: 0.264
  73. Atala A. Re: TRAF4-Mediated Ubiquitination of NGF Receptor TrkA Regulates Prostate Cancer Metastasis. J Urol. 2019 02; 201(2):230.
    View in: PubMed
    Score: 0.113
  74. Peak TC, Praharaj PP, Panigrahi GK, Doyle M, Su Y, Schlaepfer IR, Singh R, Vander Griend DJ, Alickson J, Hemal A, Atala A, Deep G. Exosomes secreted by placental stem cells selectively inhibit growth of aggressive prostate cancer cells. Biochem Biophys Res Commun. 2018 05 23; 499(4):1004-1010.
    View in: PubMed
    Score: 0.107
  75. Atala A. Re: Low CD38 Identifies Progenitor-Like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. J Urol. 2017 07; 198(1):103.
    View in: PubMed
    Score: 0.100
  76. Atala A. Re: Androgen Receptor Antagonists Compromise T Cell Response against Prostate Cancer Leading to Early Tumor Relapse. J Urol. 2017 06; 197(6):1459.
    View in: PubMed
    Score: 0.099
  77. Atala A. Re: Resistance to Docetaxel in Prostate Cancer is Associated with Androgen Receptor Activation and Loss of KDM5D Expression. J Urol. 2017 01; 197(1):154-155.
    View in: PubMed
    Score: 0.096
  78. Atala A. Re: Bone Metastasis in Prostate Cancer: Recurring Mitochondrial DNA Mutation Reveals Selective Pressure Exerted by the Bone Microenvironment. J Urol. 2016 09; 196(3):957-8.
    View in: PubMed
    Score: 0.094
  79. Atala A. Re: Dietary Flavonoid Fisetin Binds to ß-Tubulin and Disrupts Microtubule Dynamics in Prostate Cancer Cells. J Urol. 2016 08; 196(2):618.
    View in: PubMed
    Score: 0.094
  80. Atala A. Re: RNA-Seq of Single Prostate CTCs Implicates Noncanonical Wnt Signaling in Antiandrogen Resistance. J Urol. 2016 May; 195(5):1621-1622.
    View in: PubMed
    Score: 0.092
  81. Atala A. What's new in urology. J Am Coll Surg. 2004 Sep; 199(3):446-61.
    View in: PubMed
    Score: 0.042
  82. Godbey WT, Atala A. Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery. Gene Ther. 2003 Aug; 10(17):1519-27.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.